Medicxi Ventures Archives

News and Trends 10 Dec 2021

European Biotech Investors Cap Off Record Year in Fundraising

The year 2021 is closing with a biotech investment rush as Eir Ventures, Apollo Health Ventures, and Merck’s venture capital arm M Ventures raise impressive funds to speed up life sciences innovation. This year is set to break records in terms of the money flowing into institutional life science investors. With 2021 not even finished, […]

December 10, 2021 - 4 minutesmins - By Jonathan Smith

News and Trends 1 Oct 2020

Medicxi to Shake up the Biotech VC Investment Model with €200M Fund

UK-based investment firm Medicxi aims to attract more investors to the life sciences with a new fund that lets them cash in on their investments earlier than conventional funds. Last week, Medicxi closed a €200M fund called Medicxi Secondary 1 (MS1), which was co-led by the UK’s Pantheon and Switzerland’s LGT Capital Partners. The aim […]

October 1, 2020 - 4 minutesmins - By Victor Kotsev

More News! 19 Jul 2019

UK VC Medicxi Closes Third Fund with €400M to Boost European Biotech

The UK-based venture capital investment firm Medicxi has closed its third fund, totaling €400M, to nurture early- and late-stage healthcare biotech companies in Europe. The firm will begin investing in the first beneficiary companies of this fund in the next few months. The big round was raised in just six weeks, and dwarfs Medicxi’s previous […]

July 19, 2019 - 2 minutesmins - By Jonathan Smith

evotec dna damage repair parp inhibitor cancer

News and Trends 8 Jul 2019

Evotec Spinoff to Develop Cancer Drugs that Block DNA Repair

Breakpoint Therapeutics, a spinoff from the German biotech Evotec, has raised €30M to develop drugs that block DNA repair mechanisms in drug-resistant cancers. Breakpoint Therapeutics aims to develop first-in-class drugs that kill cancer cells by sabotaging their DNA repair machinery. Having taken on a number of Evotec’s drug development programs, Breakpoint aims to have its […]

July 8, 2019 - 2 minutesmins - By Jonathan Smith

Best in Biotech 28 Dec 2017

Bored Between the Holidays? Watch these Biotech Videos!

Christmas might have passed, but we have more videos for you to watch on a dreary winter day! Here are our highlights from 2017. It’s vacation time! If you’ve worn out the holiday movies, catch up on our biotech ones. It was a busy year, and we produced a lot, thanks to our new Hangouts […]

December 28, 2017 - 4 minutesmins - By Evelyn Warner

Interview 2 Nov 2017

Meet the Top Biotech Investor Who Picked His Career By Accident

Kevin Johnson, Partner at Medicxi, joined us last week for our Meetup in London. He told us how he ended as an investor despite starting in biotech. Fresh from his PhD at Cambridge, Johnson stepped into biotech and led the development of a number of human antibodies at Cambridge Antibody Technology (CAT). The company was eventually responsible for […]

November 2, 2017 - 4 minutesmins - By Alex Dale

Interview 4 Sep 2017

Meet this Blockbuster Developer turned Partner at a Headlining VC

Kevin Johnson told me the story and lessons of his career, from CTO of Cambridge Antibody Technology to General Partner at Medicxi. Since starting his biotech career as the lead developer of one of biotech’s biggest success stories, Humira, Kevin Johnson has continued in biotech as a force to be reckoned with. He joined the […]

September 4, 2017 - 7 minutesmins - By Evelyn Warner

News and Trends 13 Jul 2017

Why European Biotech Startups Should Attend American Conferences!

We all know conferences are important. To be on the same page, let’s brainstorm the word. What comes to mind? A long list of associations – networking, partnering, businesses, meetings, new people, knowledge, presentations, talks, panels, companies. We could go on and on – one thing is clear: they are one of the most effective […]

July 13, 2017 - 6 minutesmins - By External Contributor

News and Trends 15 Jun 2017

UK-based VC Launches Massive $300M Fund to Fill Gap for Late-Stage Biotech

The UK-based VC Medicxi has raised a massive $300M (€268M) fund backed by Novartis and Google’s Verily to invest in late-stage drug development. After the former life science branch of famous Index Ventures went solo in 2016 and became Medicxi, the VC was able to raise a huge sum of €210M in its first round to support early-stage, single-asset […]

June 15, 2017 - 3 minutesmins - By Melanie De Almeida

More News! 7 Mar 2017

UPDATE: Reproductive Health Biotech starts Phase III after €90M IPO

UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo transfer (ET). UPDATE (26/01/2017): ObsEva has disclosed plans to release 6.45M shares at $15 (€14) each, for a total of €90.3M. This large total reflects […]

March 7, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

More News! 9 Feb 2017

After its First Success, the Virtual Biotech Team is Back at it Again

SuperX has raised €10.3M ($11M) in Series A from Medicxi and J&J Innovation to develop anticoagulant antibodies for stroke and heart attacks. The team behind XO1, which was acquired by J&J’s Janssen back in 2015, is repeating the whole process again. Their new company, SuperX, is also focused on the discovery of anticoagulant antibodies to treat […]

February 9, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Screenshot 2016 12 23 at 6.26.13 PM e1482514040545

News and Trends 28 Dec 2016

Discussing the Future of Personalized Medicine with Biotech Experts

Personalized medicine has been a popular topic in the last few years, but when will it materialize? Experts discussed the current challenges at Labiotech Refresh. Jean-Pol Detiffe is the CEO of OncoDNA, a company using next-generation sequencing to match patients with a personalized cancer treatment. In his opinion, one of the main challenges in the […]

December 28, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us